We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sareum Holdings Plc | SAR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 27.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 27.00 | 27.00 | 27.00 | 27.00 | 27.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 20/11/2024 20:50 by criticalthinker1 Has the handbrake been put on Sareum...you tell me...7 Oct 2021 10:42 RNS Number : 3573O Sareum Holdings PLC 07 October 2021 SAREUM HOLDINGS PLC ("Sareum" or "the Company") US Patent Granted for Sareum's SDC-1802 TYK2/JAK1 Inhibitor Cambridge, UK, 7 October 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that, further to its announcement of 30 July 2021, the United States Patent and Trademark Office has now formally approved its patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the "SDC-1802 Programme"). The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development. Sareum's CSO, Dr John Reader, commented: "We are pleased to confirm the grant of this US patent for SDC-1802, adding another layer of protection around this promising candidate in key territories. Our SDC-1802 programme is in preclinical development currently and we are designing the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. We look forward to providing further updates on progress as we achieve key milestones." |
Posted at 20/11/2024 20:29 by criticalthinker1 Appreciate HBDs post but this was known nearly 4 years ago...check out what Thoth was saying...I spoke privately with him albeit our public disagreements on lse but he agreed about the points I made. This was part of a converse on lse Jan 2021albei Ahfam who got ousted as well from lse...but on the same hymn sheet...hence the recent patent approvals RE: Il-610 Jan 2021 14:55 I'll second that Thoth- This is from the research update in July in regards Lupus US Army studies- 'Specifically, it was reported that treatment with TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) reduces autoantibodies (biological markers of lupus severity) in a spontaneous mouse model of SLE. The data also provided evidence that SAR-20351 inhibits cytokines that play a critical role in lupus, including interferon-alpha, IL-6 and IL-23. The inhibition of IL-23 signalling by SAR-20351 may play a role in the decrease of autoantibodies in the lupus mouse model, as IL-23 signalling drives the differentiation of Th17 cells, which leads to autoantibody production and are pathogenic in lupus'. Big pharmas hold the gold and push it back with trolls ...noteabley on ADVFN...but thankfully they have gone...made a point to the domain owner...and they respected my point. I think the board are getting payback from the big pharma who screwed them. Large lady is warming her tonsils. The facts (imo) is the lies die and the real treatments come to fruition. All best Steadydanny |
Posted at 03/10/2024 18:31 by criticalthinker1 Henry. Its a shame one has to respond to disrupters with the detail you have given. But well done. Personally I don't suffer fools gladly. Not specifically re your response but I can definitely agree with your response re attaining information from posters.A neighbour of mine who moved away a couple years ago is an individual who is very quiet but VERY clever. He sold his company (albeit employed again to run his ipr) that is being used by the US government to attain information from hard drives that what individuals think is deleted...isn't. I can put him in contact with your own endeavours if he is accepting of the idea. But I might add he is a grey man. Moving on.... Interesting posts re our potential worth. I would like to remind individuals of this re our 1801 being very successful in ARDS re 'covid' albeit being a coronavirus....so remember 1801 went in vivo in 2021!! This is an extract of the RNS. London South East Rainbow Rare Earths discuss progress and continued flowsheet optimisation at Phalaborwa Project. Watch the interview here. Less Ads, More Data, More Tools Register for FREE Share PricesSareum Share PriceSareum Share Regulatory NewsCovid-19 Research Project Results Pin to quick picksSareum Regulatory News (SAR) SAR Share Price SAR Share Price SAR Share News SAR Share News SAR Share Chat SAR Share Chat 46 SAR Share Trades SAR Share Trades 15 SAR Live RNS SAR Live RNS Sponsored Content Sareum Information Buy SAR Shares Buy SAR Shares Add SAR to Watchlist Add SAR to Watchlist Add SAR to Alert Add SAR to Alert SAR Live PriceLast checked at 19:07:41 Share Price Information for Sareum (SAR) London Stock Exchange Share Price is delayed by 15 minutes Get Live Data Share Price: 27.50 Bid: 27.00 Ask: 28.00 Change: 0.50 (1.85%) Spread: 1.00 (3.704%)Open: 27.00High: 27.50Low: 27.00Prev. Close: 27.00 Sponsored Content Covid-19 Research Project Results 1 Jul 2021 07:00 RNS Number : 7338D Sareum Holdings PLC 01 July 2021 Sareum Holdings PLC ("Sareum" or the "Company") Completed Covid-19 Research Project Delivers Encouraging Results Cambridge, UK, 1 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project. The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801. The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. Subsequent completed in-vivo studies support the initial cellular results and indicate: · Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that · Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model. And then the shenanigans became apparent. I've been a continuous supporter of Sareum and made my points clear about decisions that were not correct..but I firmly feel we have been under attack. I mean a buy is quickly followed by a sell and then relatively noteable buys are imo supported by sells that cover them...as if a company is drip feeding a client.. All best Steadydanny So much more to say but will hold back. |
Posted at 11/9/2024 18:43 by criticalthinker1 Interesting talk on lse!...but still seem imo a bit lax in their knowledge..not all but just saying that some seem to hold court there but miss noteable facts...noteabley this re 1801Cambridge, UK, 1 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project. The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801. The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. Subsequent completed in-vivo studies support the initial cellular results and indicate: · Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that · Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model. So sareum holders don't forget that our 1801 was in vivo. So imo that's clinical work undertaken. Actually in vivo...not JUST vitro...I am so perplexed that this point is not discussed on lse. Maybe it might occur as it seems to me some of the lse posters are talkative albeit lacking in the position our company is...but talkative non the less...yes potnak I don't trust you as far as I could throw you...just my opinion. All best Steadydanny |
Posted at 02/9/2024 06:06 by z1co 02 September 2024US patent allowance for its lead programme SDC-1801 - Notice of Allowance from US Patent and Trademark Office received Cambridge, UK, 2 September 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent on SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases. The US patent, application number US2021387981, will offer substantial protection on the chemical structure of SDC-1801 and an analogue, their use in treating inflammatory diseases and in certain methods of their chemical synthesis. Sareum has now secured patent coverage in the major territories, following patent approvals by the European Patent Office, China National Intellectual Property Administration and Japan Patent Office for the same protections. The Company expects the US patent to be granted by the end of 2024, subject to the fulfilment of certain formalities with the USPTO. Dr John Reader, Sareum's Chief Scientific Officer, commented: "We are pleased to extend the patent protection for SDC-1801 on the back of the encouraging data from our Phase 1a trial, indicating our inhibitor could confer significant advantages over other TYK2/JAK1 kinase inhibitors. We remain motivated in progressing SDC-1801 through clinical development to develop new therapeutics for autoimmune diseases and cancers." |
Posted at 01/7/2024 06:32 by yzf750 Sareum Holdings plc("Sareum" or the "Company")Positive Data from SDC-1801 Phase 1 Clinical TrialCambridge, UK, 1 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases.Following the dosing of the final cohort in the Multiple Ascending Dose stage of the trial, and review of the initial data by the Safety Review Committee, the Company reports that:· Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achieved, with a half-life of between 17 and 20 hours observed, which suggests that once-daily dosing will be possible*· No deaths or serious adverse events due to SDC-1801 were reported· Although data remains blinded, there appear to be no significant changes in blood cell counts or increases in serum creatinine levels, which may be dose limiting side-effects of brepocitinib, currently the most advanced TYK2/JAK1 dual inhibitor *Half-life is an estimation of the time it takes for an initial concentration of SDC-1801 to be reduced by half in the body.The Company expects that further data, unblinded from drug/placebo recipients, including details of any mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, will be available in Q3 2024.Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "We are delighted that the dosing of subjects in the SDC-1801 clinical trial has been completed successfully and without any serious adverse events. We look forward to building a strong data package to advance SDC-1801 to the next stage of its development." Dr John Reader, Chief Scientific Officer of Sareum, added: "The success of this stage of the clinical trial demonstrates that high blood levels of a dual TYK2/JAK1 kinase inhibitor can be achieved without serious side effects. Together with the long half-life observed, we believe this potentially gives SDC-1801 significant advantages over its competitors. We're grateful to the volunteers who participated in this trial, and to the clinical staff who enabled its timely completion."- END - |
Posted at 04/6/2024 19:29 by criticalthinker1 I think Emma is in the queue Wolfie. It's tiring looking in on here and seeing the seriously unbalanced and deranged responses you give.The clue was for all to see last year in a RNS posted by Sareum (below) and since that RNS things have seen a great leap in the progression of 1801 and 1802 will follow and 737 ticking along despite your lies to acknowledge the proof I had it was still progressing. RNS Sareum announces two new granted patents, including first patent specifically for SDC-1801 Cambridge, UK, 26 June 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the first patent specifically relating to SDC-1801, its lead TYK2/JAK1 kinase inhibitor, has been granted in China. Further, a patent has been formally granted for SDC-1802 and several analogues in the United States, extending the scope of protection beyond immuno-oncology. Dr John Reader, Sareum's Chief Scientific Officer, commented: "We're delighted to have the first patent granted for SDC-1801, our lead development programme which recently advanced into a Phase 1a clinical trial in Australia. We look forward to being able to strengthen our intellectual property around this asset in other territories in due course." "Separately, we are really pleased to have extended the scope of patent protection for SDC-1802 in the US. Although oncology remains the primary focus of this asset, this bulwarks our intellectual property position and gives us optionality to explore opportunities in other therapeutic areas." SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune dermatological condition affecting more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion. Sareum recently announced that it has begun dosing healthy subjects in a Phase 1a clinical trial for SDC-1801, in Australia. The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders. This is the first patent grant issued to Sareum for SDC-1801 in any territory. Patent applications in Europe (EP3864009), the US (US2021387981) and other territories are still under review. SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy. Sareum continues to work on the translational studies needed to support the development of SDC-1802, defining the optimal cancer application prior to completing toxicology and manufacturing studies. The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-oncology. Just read that and see where we are now! Look at the various avenues the drugs can be adopted in! Good luck to genuine holders. I'm convinced as I mentioned before PH are trying to play the share price before imminent fantastic update. They are a despicable company. Its very interesting the timing of the trolls appearing. |
Posted at 25/5/2024 19:17 by criticalthinker1 Re 1801 this from 2023..oh how we have come on 4.5. SAR-20347 SAR-20347 is an oral inhibitor of Tyk2 and Jak1 with selectivity over Jak2 and Jak3. Preclinical assays demonstrated that SAR-20347 inhibited IL-12, IL-23 and IFN-α signaling [22]. Both Tyk2 mutant mice and mice treated with SAR-20347 showed significant reduction of IL-6 and IL-17 in imiquimod-induced skin lesions, but only SAR-20347-treated mice presented reduced levels of IL-23, decreased keratinocyte proliferation and improved clinical score [22]. In addition, SAR-20347-treated mice manifested lower IL-17 gene expression compared to Tyk2 mutant mice [22]. In this model, Works et al. demonstrated that SAR-20347 treated mice showed an almost complete loss of IL-22 gene expression in skin lesions, and they postulate that SAR-20347 would impair the ability of Th17 and γδ cells to induce IL-22 [22]. IL-22 is required for development of autoreactive Th17 cells [77,78]. However, not only IL-22 production was impaired, since IL-22 signaling was also affected in vitro in a human colonic cell line, and STAT3 phosphorylation dependent of IL-22 was completely blocked [22]. Blocking both Tyk2 and Jak1 in this study was more effective than inhibition of Tyk2 alone at reducing psoriasis-like disease severity, keratinocyte proliferation, as well as IL-23, IL-17, IL-6, IL-22, and antimicrobial peptide gene expression, and the authors postulate that targeting a combination of Jak1 and Tyk2 using an orally available inhibitor may be a viable approach for treating psoriasis, but currently there are no ongoing or completed clinical trials for SAR-20347 [22]. The bodies in 'control' of certain narratives know full well what Sareum is undertaking. This is going to make Novacyt huge rise look like a blip. 1802 is going to be on the tail end and the results of 1801 will be very significant in its future All best Steadydanny |
Posted at 07/4/2024 20:24 by peaceandlove Wolf, the rampers are on a different planet to me. Sareum's current market value is correct, £8million based on the following.1) No revenue. 2) Dilution with more on the cards. 3) As you say 737 was turned down by GSK. 4) None of Sareum's products are proven. 5) Phase 1 of the clinical trial is safety only. 6) The MHRA turned Sareum down for a clinical trial in the UK. This is an enormous red flag for me. 7) Board are still taking large salaries as 'working capital'. 8) It almost 20 years since Sareum were listed on AIM. 20 years and the share price 92% down. 9) No license deals even though Sareum's business model is to license pre clinical or early on in the clinical trial. To be frank, Sareum have had 20 years and produced f all. What does that tell you?????? Oh yeah this is the year of rerate, the year of license deals, the year of 1801, the year of 737, the year of revenue. Come on Sar.... 😆🤣 |
Posted at 28/8/2023 20:17 by criticalthinker1 A timely reminder of why I for one am invested in Sareum, and I feel this RNS is pivotal in Sareums future, albeit you will note the time delays, which I hasten to add are NOT Sareums fault. But diligently overcome imo.Everything in this RNS and especially the part re cytokines and superiority to dexamethasone and invivo trials and finally the indication of continuance of looking at trial data re covid 19....I wonder if the shake is over...you can read Tim's follow up to this RNS, but just thought I'd share the nuts and bolts. 01 Jul 21 Sareum Holdings PLC - Covid-19 Research Project Results RNS Number : 7338D Sareum Holdings PLC 01 July 2021 Sareum Holdings PLC ("Sareum" or the "Company") Completed Covid-19 Research Project Delivers Encouraging Results Cambridge, UK, 1 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project. The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801. The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. Subsequent completed in-vivo studies support the initial cellular results and indicate: · Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that · Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model. Subject to successful completion of the ongoing preclinical toxicology studies, requisite approvals and financing, the Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field. I am of the opinion we are in an extremely exciting period of Sareums progression and from what I'm garnering from msm and covid ...the ongoing trial of 1801 and 'potentially' pari passu 1802 is imo worthy of a squeaky chair update when 'allowed' and 'reportable' Those recent Patents will prove very useful 'if' multiple licences are requested. Best regards Steadydanny |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
